论文部分内容阅读
探讨腺肽α1联合恩替卡韦对慢性乙型肝炎患者免疫功能及复发的影响.选取2013年3月～ 2014年5月在该院进行治疗的慢性乙型肝炎患者共82例,随机分为研究组和对照组,每组各41例,其中对照组采用恩替卡韦单独给药治疗,研究组采用腺肽α1联合恩替卡韦给药治疗,研究两组患者治疗前后免疫功能的变化及病情的复发情况.研究组患者的CD4+及CD8+水平在治疗前与对照组无显著差异,治疗后明显高于对照组,而CD4+/CD8+研究组治疗后已恢复正常水平,免疫调节能力大幅恢复,明显优于对照组.两组患者治疗前各项肝功能指数无显著差异,治疗后肝功能均有一定改善,除去ALT外其余指标治疗后研究组均优于对照组.治愈后前3个月两组患者的复发情况无显著变化,6 ～12月期间对照组患者的复发情况开始逐渐升高,最终研究组的复发人数明显低于对照组.腺肽α1联合恩替卡韦对慢性乙型肝炎患者免疫功能及复发有积极的作用,能够有效的提高患者的治疗体验和预后,值得在临床上推广.“,”To investigate the effect of adenovirus alpha 1 combined with entecavir on immune function and recurrence in patients with chronic hepatitis B,from March 2013 to May 2014 in our hospital for treatment of chronic hepatitis B patients.A total of 82 patients were randomly divided into study group and control group,41 cases in each group.The control group was treated with entecavir monotherapy treatment,the study group using gland peptide alpha 1 entecavir combined drug treatment,the recurrence of change on the immune function and disease before and after treatment in two groups of patients was studied.CD4+ and CD8+ levels of patients in the study group before treatment had no significant difference with control group,after treatment was significantly higher than those in the control group,while the CD4+/CD8+ research group after treatment has returned to normal levels,immune regulation ability significantly restored,significantly better than those in the control group.There was no significant difference in the liver function index between the two groups before treatment.The liver function was improved after the treatment,except the ALT,and the treatment group was better than the control group after the treatment.In the first three months after treatment,there was no significant change in the recurrence of the two groups.During the 6 ～ 12 months,the recurrence rate of the control group began to rise gradually,and the number of recurrences in the study group was significantly lower than that in the control group.Adenovirus alpha 1 combined with entecavir has positive effects on immune function and recurrence in patients with chronic hepatitis B.It can effectively improve the treatment experience and prognosis of patients with chronic hepatitis B,and is worthy of clinical promotion.